APA (7th ed.) Citation

Esler, M., Kjeldsen, S. E., Pathak, A., Grassi, G., Kreutz, R., & Mancia, G. (2022). Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified. Blood Pressure, 31(1), 210. https://doi.org/10.1080/08037051.2022.2110858

Chicago Style (17th ed.) Citation

Esler, Murray, Sverre E. Kjeldsen, Atul Pathak, Guido Grassi, Reinhold Kreutz, and Giuseppe Mancia. "Diverse Pharmacological Properties, Trial Results, Comorbidity Prescribing and Neural Pathophysiology Suggest European Hypertension Guideline Downgrading of Beta-blockers Is Not Justified." Blood Pressure 31, no. 1 (2022): 210. https://doi.org/10.1080/08037051.2022.2110858.

MLA (9th ed.) Citation

Esler, Murray, et al. "Diverse Pharmacological Properties, Trial Results, Comorbidity Prescribing and Neural Pathophysiology Suggest European Hypertension Guideline Downgrading of Beta-blockers Is Not Justified." Blood Pressure, vol. 31, no. 1, 2022, p. 210, https://doi.org/10.1080/08037051.2022.2110858.